1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Miller K and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev.
34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ruys AT, Tanis PJ, Naftegaal ID, van
Duijvendijk P, Verhoef C, Porte RJ and van Gulik TM: Surgical
treatment of renal cell cancer liver metastases: A population-based
study. Ann Surg Oncol. 18:1932–1938. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Guéhenneux F, Duret L, Callanan MB, et al:
Cloning of the mouse BTG3 gene and definition of a new gene family
(the BTG family) involved in the negative control of the cell
cycle. Leukemia. 11:370–375. 1997. View Article : Google Scholar
|
6
|
Rouault JP, Prévôt D, Berthet C, Birot AM,
Billaud M, Magaud JP and Corbo L: Interaction of BTG1 and
p53-regulated BTG2 gene products with mCaf1, the murine homolog of
a component of the yeast CCR4 transcriptional regulatory complex. J
Biol Chem. 273:22563–22569. 1998. View Article : Google Scholar : PubMed/NCBI
|
7
|
Prévôt D, Voeltzel T, Birot AM, Morel AP,
Rostan MC, Magaud JP and Corbo L: The leukemia-associated protein
Btg1 and the p53-regulated protein Btg2 interact with the
homeoprotein Hoxb9 and enhance its transcriptional activation. J
Biol Chem. 275:147–153. 2000. View Article : Google Scholar : PubMed/NCBI
|
8
|
Corjay MH, Kearney MA, Munzer DA, Diamond
SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly
expressed in apoptotic cells in macrophage-rich areas of advanced
lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab
Invest. 78:847–858. 1998.PubMed/NCBI
|
9
|
Berthet C, Guéhenneux F, Revol V, et al:
Interaction of PRMT1 with BTG/TOB proteins in cell signalling:
UMolecular analysis and functional aspects. Genes Cells. 7:29–39.
2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Bedford MT and Richard S: Arginine
methylation an emerging regulator of protein function. Mol Cell.
18:263–272. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Rouault JP, Rimokh R, Tessa C, et al:
BTG1, a member of a new family of antiproliferative genes. EMBO J.
11:1663–1670. 1992.PubMed/NCBI
|
12
|
Ito Y, Suzuki T, Yoshida H, et al:
Phosphorylation and inactivation of Tob contributes to the
progression of papillary carcinoma of the thyroid. Cancer Lett.
220:237–242. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Iwanaga K, Sueoka N, Sato A, et al:
Alteration of expression or phosphorylation status of tob, a novel
tumor suppressor gene product, is an early event in lung cancer.
Cancer Lett. 202:71–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yoneda M, Suzuki T, Nakamura T, et al:
Deficiency of antiproliferative family protein Ana correlates with
development of lung adenocarcinoma. Cancer Sci. 100:225–232. 2009.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Kawakubo H, Brachtel E, Hayashida T, et
al: Loss of B-cell translocation gene-2 in estrogen
receptor-positive breast carcinoma is associated with tumor grade
and overexpression of cyclin d1 protein. Cancer Res. 66:7075–7082.
2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhu R, Zou ST, Wan JM, Li W, Li XL and Zhu
W: BTG1 inhibits breast cancer cell growth through induction of
cell cycle arrest and apoptosis. Oncol Rep. 30:2137–2144.
2013.PubMed/NCBI
|
17
|
Sun GG, Lu YF, Cheng YJ and Hu WN: The
expression of BTG1 is downregulated in NSCLC and possibly
associated with tumor metastasis. Tumour Biol. 35:2949–2957. 2014.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Doidge R, Mittal S, Aslam A and Winkler
GS: The anti-proliferative activity of BTG/TOB proteins is mediated
via the Caf1a (CNOT7) and Caf1b (CNOT8) deadenylase subunits of the
Ccr4-not complex. PLoS One. 7:e513312012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Dhar S, Vemulapalli V, Patananan AN, et
al: Loss of the major Type I arginine methyltransferase PRMT1
causes substrate scavenging by other PRMTs. Sci Rep. 3:13112013.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhang R, Li X, Liang Z, et al: Theoretical
insights into catalytic mechanism of protein arginine
methyltransferase 1. PLoS One. 8:e724242013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yu Z, Chen T, Hébert J, Li E and Richard
S: A mouse PRMT1 null allele defines an essential role for arginine
methylation in genome maintenance and cell proliferation. Mol Cell
Biol. 29:2982–2996. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Yoshimatsu M, Toyokawa G, Hayami S, et al:
Dysregulation of PRMT1 and PRMT6, Type I arginine
methyltransferases, is involved in various types of human cancers.
Int J Cancer. 128:562–573. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Cho JH, Lee MK, Yoon KW, Lee J, Cho SG and
Choi EJ: Arginine methylation-dependent regulation of ASK1
signaling by PRMT1. Cell Death Differ. 19:859–870. 2012. View Article : Google Scholar : PubMed/NCBI
|